Nurix Therapeutics (NRIX) Stock Forecast, Price Target & Predictions
NRIX Stock Forecast
Nurix Therapeutics stock forecast is as follows: an average price target of $27.57 (represents a 11.17% upside from NRIX’s last price of $24.80) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.
NRIX Price Target
The average price target for Nurix Therapeutics (NRIX) is $27.57 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $25.00. This represents a potential 11.17% upside from NRIX's last price of $24.80.
NRIX Analyst Ratings
According to 16 Wall Street analysts, Nurix Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for NRIX stock is 0 'Strong Buy' (0.00%), 12 'Buy' (75.00%), 4 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Nurix Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 05, 2024 | Brian Skorney | Robert W. Baird | $26.00 | $24.44 | 6.38% | 4.84% |
| Aug 14, 2024 | Matthew Biegler | Oppenheimer | $27.00 | $21.92 | 23.18% | 8.87% |
| Jun 27, 2024 | Gregory Renza | RBC Capital | $26.00 | $20.70 | 25.60% | 4.84% |
| Jun 18, 2024 | Robert Burns | H.C. Wainwright | $26.00 | $18.44 | 41.00% | 4.84% |
| Jun 05, 2024 | Tyler Van Buren | Piper Sandler | $35.00 | $15.95 | 119.44% | 41.13% |
| Apr 11, 2024 | Gregory Renza | RBC Capital | $23.00 | $15.69 | 46.59% | -7.26% |
| Apr 11, 2024 | Joel Beatty | Robert W. Baird | $25.00 | $15.69 | 59.34% | 0.81% |
| Dec 13, 2022 | - | Leerink Partners | $28.00 | $12.26 | 128.38% | 12.90% |
| May 31, 2022 | Derek Archila | Wells Fargo | $25.00 | $10.09 | 147.77% | 0.81% |
The latest Nurix Therapeutics stock forecast, released on Sep 05, 2024 by Brian Skorney from Robert W. Baird, set a price target of $26.00, which represents a 6.38% increase from the stock price at the time of the forecast ($24.44), and a 4.84% increase from NRIX last price ($24.80).
Nurix Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 4 | 7 |
| Avg Price Target | $26.00 | $26.25 | $26.86 |
| Last Closing Price | $24.80 | $24.80 | $24.80 |
| Upside/Downside | 4.84% | 5.85% | 8.31% |
In the current month, the average price target of Nurix Therapeutics stock is $26.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 4.84% increase as opposed to Nurix Therapeutics's last price of $24.80. This month's average price target is down -0.95% compared to last quarter, and down -3.20% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | RBC Capital | Buy | Buy | Hold |
| Sep 04, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Sep 04, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 31, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Jul 31, 2024 | Stephens | Buy | Buy | Hold |
| Jul 15, 2024 | Barclays | Overweight | Overweight | Hold |
| Jul 14, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jul 12, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 12, 2024 | RBC Capital | Outperform | Outperform | Hold |
Nurix Therapeutics's last stock rating was published by RBC Capital on Sep 04, 2024. The company gave NRIX a "Buy" rating, the same as its previous rate.
Nurix Therapeutics Financial Forecast
Nurix Therapeutics Revenue Forecast
| Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $18.47M | $30.68M | - | - | $10.79M | $11.43M | - | $7.40M | $10.25M | $7.09M | - | $6.69M | $4.08M |
| Avg Forecast | $17.10M | $17.10M | $16.27M | $16.27M | $15.99M | $13.48M | $22.11M | $17.13M | $34.14M | $11.94M | $26.24M | $10.96M | $17.17M | $11.45M | $10.50M | $9.27M | $13.19M | $8.54M | $8.23M | $8.68M | $3.94M | $6.35M |
| High Forecast | $17.10M | $17.10M | $16.27M | $16.27M | $15.99M | $17.88M | $22.11M | $17.13M | $84.62M | $11.94M | $26.24M | $10.96M | $17.17M | $13.74M | $12.60M | $16.21M | $23.07M | $14.94M | $14.38M | $15.17M | $6.90M | $11.10M |
| Low Forecast | $17.10M | $17.10M | $16.27M | $16.27M | $15.99M | $11.89M | $22.11M | $17.13M | $5.99M | $11.94M | $26.24M | $10.96M | $17.17M | $9.16M | $8.40M | $7.08M | $10.08M | $6.53M | $6.28M | $6.63M | $3.01M | $4.85M |
| # Analysts | 3 | 4 | 5 | 4 | 3 | 7 | 3 | 3 | 7 | 4 | 5 | 8 | 7 | 17 | 9 | 2 | 3 | 3 | 3 | 3 | 4 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.55% | 1.17% | - | - | 0.94% | 1.09% | - | 0.56% | 1.20% | 0.86% | - | 1.70% | 0.64% |
Nurix Therapeutics's average Quarter revenue forecast for Dec 23 based on 7 analysts is $34.14M, with a low forecast of $5.99M, and a high forecast of $84.62M. NRIX's average Quarter revenue forecast represents a 84.86% increase compared to the company's last Quarter revenue of $18.47M (Aug 23).
Nurix Therapeutics EBITDA Forecast
| Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 4 | 3 | 7 | 3 | 3 | 7 | 4 | 5 | 8 | 7 | 17 | 9 | 2 | 3 | 3 | 3 | 3 | 4 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-36.63M | $-23.43M | - | - | $-43.83M | $-43.08M | - | $-33.61M | $-28.21M | $-25.60M | - | $-19.23M | $-17.97M |
| Avg Forecast | $-15.87M | $-15.87M | $-15.09M | $-15.09M | $-14.83M | $-12.50M | $-20.51M | $-51.32M | $-31.67M | $-11.07M | $-24.34M | $-46.66M | $-15.93M | $-31.50M | $-113.17M | $-36.88M | $-25.82M | $-28.64M | $-23.77M | $-14.85M | $-3.66M | $-11.09M |
| High Forecast | $-15.87M | $-15.87M | $-15.09M | $-15.09M | $-14.83M | $-11.03M | $-20.51M | $-41.06M | $-5.56M | $-11.07M | $-24.34M | $-37.32M | $-15.93M | $-25.20M | $-90.54M | $-29.51M | $-20.65M | $-22.91M | $-19.02M | $-11.88M | $-2.80M | $-8.87M |
| Low Forecast | $-15.87M | $-15.87M | $-15.09M | $-15.09M | $-14.83M | $-16.58M | $-20.51M | $-61.59M | $-78.51M | $-11.07M | $-24.34M | $-55.99M | $-15.93M | $-37.81M | $-135.81M | $-44.26M | $-30.98M | $-34.37M | $-28.52M | $-17.82M | $-6.40M | $-13.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.31% | 0.96% | - | - | 1.39% | 0.38% | - | 1.30% | 0.99% | 1.08% | - | 5.25% | 1.62% |
undefined analysts predict NRIX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Nurix Therapeutics's previous annual EBITDA (undefined) of $NaN.
Nurix Therapeutics Net Income Forecast
| Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 4 | 3 | 7 | 3 | 3 | 7 | 4 | 5 | 8 | 7 | 17 | 9 | 2 | 3 | 3 | 3 | 3 | 4 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | $-36.98M | $-21.79M | - | - | $-44.70M | $-45.09M | - | $-37.70M | $-28.84M | $-26.38M | - | $-19.91M | $-17.84M |
| Avg Forecast | $-47.41M | $-47.72M | $-46.94M | $-46.47M | $-42.90M | $-41.60M | $-39.59M | $-54.48M | $-30.97M | $-52.30M | $-35.38M | $-49.52M | $-48.84M | $-32.20M | $-122.99M | $-39.15M | $-28.96M | $-29.27M | $-24.50M | $-15.30M | $-29.19M | $-11.43M |
| High Forecast | $-47.41M | $-47.72M | $-46.94M | $-46.47M | $-42.90M | $-29.80M | $-39.59M | $-43.58M | $21.25M | $-52.30M | $-35.38M | $-39.62M | $-48.84M | $-25.76M | $-98.39M | $-31.32M | $-23.17M | $-23.42M | $-19.60M | $-12.24M | $-20.24M | $-9.14M |
| Low Forecast | $-47.41M | $-47.72M | $-46.94M | $-46.47M | $-42.90M | $-53.40M | $-39.59M | $-65.37M | $-61.93M | $-52.30M | $-35.38M | $-59.43M | $-48.84M | $-38.64M | $-147.59M | $-46.98M | $-34.75M | $-35.13M | $-29.40M | $-18.36M | $-57.60M | $-13.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.71% | 0.62% | - | - | 1.39% | 0.37% | - | 1.30% | 0.99% | 1.08% | - | 0.68% | 1.56% |
Nurix Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NRIX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Nurix Therapeutics SG&A Forecast
| Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 4 | 3 | 7 | 3 | 3 | 7 | 4 | 5 | 8 | 7 | 17 | 9 | 2 | 3 | 3 | 3 | 3 | 4 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | $10.62M | $11.68M | - | - | $9.75M | $9.65M | - | $8.82M | $8.34M | $7.51M | - | $6.25M | $4.34M |
| Avg Forecast | $12.63M | $12.63M | $12.01M | $12.01M | $11.81M | $9.96M | $16.33M | $11.82M | $25.22M | $8.82M | $19.38M | $10.74M | $12.68M | $9.32M | $7.76M | $8.49M | $6.77M | $8.47M | $6.97M | $4.12M | $2.91M | $2.68M |
| High Forecast | $12.63M | $12.63M | $12.01M | $12.01M | $11.81M | $13.20M | $16.33M | $14.18M | $62.50M | $8.82M | $19.38M | $12.89M | $12.68M | $11.18M | $9.31M | $10.19M | $8.13M | $10.16M | $8.37M | $4.94M | $5.09M | $3.21M |
| Low Forecast | $12.63M | $12.63M | $12.01M | $12.01M | $11.81M | $8.78M | $16.33M | $9.46M | $4.42M | $8.82M | $19.38M | $8.60M | $12.68M | $7.45M | $6.20M | $6.80M | $5.42M | $6.78M | $5.58M | $3.29M | $2.23M | $2.14M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.20% | 0.60% | - | - | 1.05% | 1.24% | - | 1.30% | 0.99% | 1.08% | - | 2.15% | 1.62% |
Nurix Therapeutics's average Quarter SG&A projection for Dec 23 is $25.22M, based on 7 Wall Street analysts, with a range of $4.42M to $62.50M. The forecast indicates a 137.37% rise compared to NRIX last annual SG&A of $10.62M (Aug 23).
Nurix Therapeutics EPS Forecast
| Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 4 | 3 | 7 | 3 | 3 | 7 | 4 | 5 | 8 | 7 | 17 | 9 | 2 | 3 | 3 | 3 | 3 | 4 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.68 | $-0.40 | - | - | $-0.88 | $-1.00 | - | $-0.85 | $-0.65 | $-0.60 | - | $-0.51 | $-0.57 |
| Avg Forecast | $-0.76 | $-0.77 | $-0.75 | $-0.74 | $-0.69 | $-0.67 | $-0.63 | $-0.78 | $-0.50 | $-0.84 | $-0.57 | $-0.87 | $-0.78 | $1.27 | $1.15 | $-0.88 | $-0.68 | $-0.62 | $-0.54 | $-0.45 | $-0.53 | $-0.41 |
| High Forecast | $-0.76 | $-0.77 | $-0.75 | $-0.74 | $-0.69 | $-0.48 | $-0.63 | $-0.78 | $0.34 | $-0.84 | $-0.57 | $-0.87 | $-0.78 | $1.27 | $1.15 | $-0.61 | $-0.47 | $-0.43 | $-0.37 | $-0.31 | $-0.37 | $-0.29 |
| Low Forecast | $-0.76 | $-0.77 | $-0.75 | $-0.74 | $-0.69 | $-0.86 | $-0.63 | $-0.78 | $-0.99 | $-0.84 | $-0.57 | $-0.87 | $-0.78 | $1.27 | $1.15 | $-1.73 | $-1.35 | $-1.23 | $-1.06 | $-0.89 | $-1.05 | $-0.81 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.81% | 0.71% | - | - | -0.69% | -0.87% | - | 1.25% | 1.05% | 1.12% | - | 0.96% | 1.38% |
According to undefined Wall Street analysts, Nurix Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NRIX previous annual EPS of $NaN (undefined).
Nurix Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LYEL | Lyell Immunopharma | $1.23 | $9.50 | 672.36% | Hold |
| NKTX | Nkarta | $5.71 | $21.60 | 278.28% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| STTK | Shattuck Labs | $3.81 | $12.00 | 214.96% | Buy |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| PRLD | Prelude Therapeutics | $2.77 | $6.25 | 125.63% | Sell |
| FHTX | Foghorn Therapeutics | $9.72 | $18.00 | 85.19% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| NRIX | Nurix Therapeutics | $24.80 | $27.57 | 11.17% | Buy |
| KYMR | Kymera Therapeutics | $46.08 | $51.10 | 10.89% | Buy |
NRIX Forecast FAQ
Is Nurix Therapeutics a good buy?
Yes, according to 16 Wall Street analysts, Nurix Therapeutics (NRIX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 75.00% of NRIX's total ratings.
What is NRIX's price target?
Nurix Therapeutics (NRIX) average price target is $27.57 with a range of $25 to $35, implying a 11.17% from its last price of $24.8. The data is based on 16 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Nurix Therapeutics stock go up soon?
According to Wall Street analysts' prediction for NRIX stock, the company can go up by 11.17% (from the last price of $24.8 to the average price target of $27.57), up by 41.13% based on the highest stock price target, and up by 0.81% based on the lowest stock price target.
Can Nurix Therapeutics stock reach $40?
NRIX's average twelve months analyst stock price target of $27.57 does not support the claim that Nurix Therapeutics can reach $40 in the near future.
What is Nurix Therapeutics's current price target trend?
1 Wall Street analyst forecast a $26 price target for Nurix Therapeutics (NRIX) this month, up 4.84% from its last price of $24.8. Compared to the last 3 and 12 months, the average price target increased by 5.85% and increased by 8.31%, respectively.
Did the NRIX's actual financial results beat the analysts' financial forecasts?
Based on Nurix Therapeutics's last annual report (Nov 2021), the company's revenue was $29.75M, which missed the average analysts forecast of $38.64M by -23.01%. Apple's EBITDA was $-118M, beating the average prediction of $-93.079M by 26.65%. The company's net income was $-117M, beating the average estimation of $-98.033M by 19.55%. Apple's SG&A was $31.2M, beating the average forecast of $26.33M by 18.49%. Lastly, the company's EPS was $-2.73, beating the average prediction of $-2.291 by 19.14%. In terms of the last quarterly report (Aug 2023), Nurix Therapeutics's revenue was $18.47M, beating the average analysts' forecast of $11.94M by 54.71%. The company's EBITDA was $-36.628M, beating the average prediction of $-11.075M by 230.74%. Nurix Therapeutics's net income was $-36.982M, missing the average estimation of $-52.304M by -29.29%. The company's SG&A was $10.62M, beating the average forecast of $8.82M by 20.49%. Lastly, the company's EPS was $-0.68, missing the average prediction of $-0.839 by -18.90%